101 results about "Metabolism disorder" patented technology

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. Lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit / hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.

The invention relates to the technical field of microorganisms, in particular to application of pediococcus acidilactici ZJUIDS13 in improvement of liver diseases, including improvement of alcoholic liver diseases and improvement of fatty liver diseases related to metabolic dysfunction. The pediococcus acidilactici ZJUIDS13 has relatively strong capability of protecting liver injury induced by alcohol, and can improve the states of liver injury and lipid metabolism disorder caused by high fat diet.

The present invention relates to a use of benzethonium chloride in preparing a drug for improving or treating non-alcoholic fatty liver disease, and relates to the technical field of new uses of products. The present invention discovers for the first time a new use of benzethonium chloride for improving or treating non-alcoholic fatty liver disease. Benzethonium chloride can reduce hepatocyte lipid deposition and regulate hepatocyte lipid metabolism disorder by intervening in a cell lipid deposition model; it can improve liver lipid accumulation in mice caused by lipid metabolism disorder by administering through the digestive tract, and can improve liver coefficient, liver function, hepatic lobular inflammation, and liver fibrosis. The benzethonium chloride of the present invention can be used for the preparation of drugs for improving or treating non-alcoholic fatty liver disease. The benzethonium chloride of the present invention can inhibit the expression of human apolipoprotein C3, thereby reducing the generation of lipids, and is applied to drugs for treating non-alcoholic fatty liver disease, opening up a new use of benzethonium chloride and providing a new drug option for treating non-alcoholic fatty liver disease.

The invention discloses a lactobacillus rhamnosus GYX-9 strain and an application of the lactobacillus rhamnosus GYX-9 strain. The lactobacillus rhamnosus GYX-9 disclosed by the invention can be used for regulating the problems of blood lipid metabolism disorder, liver lipid accumulation or pathological injury and the like caused by high-fat diet. The lactobacillus rhamnosus GYX-9 disclosed by the invention can be used for reducing the level of TNF-alpha, increasing the content of IL-10 and regulating colonic immune disorder; the abundance of intestinal microbiome communities is adjusted; according to the invention, the lactobacillus rhamnosus GYX-9 is combined to regulate and control the metabolic disorder caused by high-fat diet on the basis of'intestinal flora-intestine-liver axis'. The normal-temperature viable bacterium fermented milk with the viable bacterium number not less than 108 cfu / mL is also prepared, the normal-temperature viable bacterium fermented milk has remarkable capabilities of lowering cholesterol, combining taurocholate and inhibiting pancreatic lipase, and the pancreatic lipase inhibition rate can reach 67.06%.

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. Lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit / hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid- and -metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

The invention discloses an application of morchella enzymolysis polysaccharide in regulating lipid metabolism disorder. The morchella enzymolysis polysaccharide disclosed by the invention can be used for regulating lipid metabolism disorder, regulating intestinal flora and preventing liver injury, oxidative stress and inflammation. The morchella esculenta adopted by the invention is medicinal and edible morchella esculenta, is free of chemical modification and is high in safety; and the enzymolysis process is low in cost, easy to scale and suitable for functional food or medicine development. In addition, the invention provides the application value of 8-aminooctanoic acid as a lipid metabolism disorder marker for the first time, and expands the application scene of EMIP in preparation of diversified products for regulating intestinal flora, improving liver injury, reducing oxidative stress and the like.

Provided are a GLP-1GIP analog, an FGF21 protein, a trifunctional protein, and use thereof. The trifunctional protein comprises the GLP-1 / GIP analog and the FGF21 protein. Further provided is use of the GLP-1 / GIP analog, the FGF21 protein, and the trifunctional protein in the preparation of a drug for preventing and / or treating diseases related to GLP-1, GIP, and / or FGF21. The provided GLP-1 / GIP analog, FGF21 protein, and trifunctional protein can synergistically regulate blood glucose and lipid levels in vivo, meet multiple needs in patients with type 2 diabetes, including lowering blood glucose, alleviating hepatic steatosis, promoting weight loss, ameliorating circulating lipid metabolism disorder, etc., and have better biological safety and tolerability and longer in vivo half-lives.

The invention provides a rhizoma polygonati extract as well as a preparation method and application thereof in prevention and control of glucose and lipid metabolism disorder. According to the invention, an effective component group consisting of effective parts of flavonoids and saponins is extracted from a traditional Chinese medicinal material polygonatum sibiricum, the sum of the actual contents accounts for more than 50% of the total weight of the polygonatum sibiricum extract, and meanwhile, the effective component group is used for preparing medicines for preventing and / or treating impaired glucose tolerance and glucose and lipid metabolism disorder. The traditional Chinese medicine composition is clear in curative effect, controllable in quality and easy to industrialize in preparation process, various proper dosage forms can be prepared according to clinical requirements, and a convenient, effective, stable and controllable modern traditional Chinese medicine is provided for clinical application.

The invention discloses a GLP-1 GIP analogue, an FGF21 protein, a three-function protein and an application thereof. The trifunctional protein comprises a GLP-1 / GIP analogue and an FGF21 (Fibroblast Growth Factor 21) protein. The invention also discloses application of the GLP-1 / GIP analogue, the FGF21 protein and the three-function protein in preparation of medicines for preventing and / or treating diseases related to GLP-1, GIP and / or FGF21. The GLP-1 / GIP analogue, the FGF21 protein and the three-function protein provided by the invention can synergistically regulate blood sugar and lipid levels in vivo, meet multiple requirements of patients with type 2 diabetes for reducing blood sugar, relieving liver fatty degeneration, reducing weight, improving circulating lipid metabolism disorder and the like, and are better in biological safety and tolerance and longer in in-vivo half-life period.

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid-and-metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

The invention discloses a long-acting GGG three-target agonist, and the compound provided by the invention simultaneously achieves nM-level excellent agonist ability on three targets of GLP-l / GIP / GCGR, and can fully excite corresponding target organ tissue cells. The compound provided by the invention can promote insulin secretion and reduce blood sugar; in addition, ingestion can be inhibited, gastric emptying can be delayed, energy consumption can be increased, and finally the weight reduction effect can be observed. The compound provided by the invention can reduce pancreatic beta-cell apoptosis, increase the quantity of pancreatic beta-cells and improve functions of pancreatic cells. The compound disclosed by the invention can also improve blood fat, reduce liver fat accumulation and inhibit liver inflammation development. The compound or the composition can be used for preventing and / or treating metabolic disorder diseases and related complications thereof. The compound or the composition can be used for treating bone diseases related to endocrine diseases, metabolic disorders, nephropathy and the like, such as osteoporosis and osteoarthritis.

The invention discloses application of a compound AZD5718 in preparation of a medicine for preventing and / or treating cholestatic liver diseases, and belongs to the field of biological medicines. The compound AZD5718 can effectively improve hepatocyte damage and bile metabolism disorder caused by Mdr2 gene deletion, provides solid experimental data support for developing novel drugs for treating cholestatic liver diseases, is expected to provide differentiated therapeutic drug choices for clinic, and has important medical value and social significance.

Provided is a fusion protein, the fusion protein containing a GLP-1 polypeptide and an immunoglobulin Fc domain, wherein the GLP-1 polypeptide is covalently linked to the immunoglobulin Fc domain, the GLP-1 polypeptide is selected from human GLP-1(9-37) and human GLP-1(9-36) amides, and the GLP-1 polypeptide contains G22E and / or R36G substitutions relative to a natural human GLP-1 polypeptide. The human GLP-1(9-37) and human GLP-1(9-36) amides are products respectively resulting from losing two amino acids at the N-terminus of natural human GLP-1(7-37) and human GLP-1(7-36, by means of DPP4 enzyme degradation, and were previously considered as biologically inactive fragments. Provided are a polynucleotide encoding the fusion protein, a vector and cell containing the polynucleotide, and the use thereof, for example, in the preparation of drugs for treating metabolic diseases related to lipid metabolism disorders, complications of metabolic diseases, neurodegenerative diseases and other related diseases.

To provide a method for treating a GLP-1 / GLP-1 1R related disease such as a carbohydrate metabolism disorder-related disease, a fat metabolism disorder-related disease, or a GLP-1 / GLP-1 1R related nervous system disease, and to provide a medicament.SOLUTION: Provided is a method for treating a disease by regulating GLP-1 / GLP-1 1R, comprising administering an effective amount of GLP-1 to a subject.SELECTED DRAWING: None

Disclosed in the present invention are a compound for preventing and treating related diseases caused by an aldehyde metabolism disorder and the use thereof. The compound is a compound as shown in formula (I), or a stereoisomer, a tautomer, a solvate, and a pharmaceutically acceptable salt of the compound as shown in formula (I).

The invention discloses application of rutin hydrate in preventing and treating repeated embryo planting failure, and belongs to the technical field of assisted reproduction. It is found for the first time that CD36 is a key membrane protein for lipid transport and uptake of EECs, rutin hydrate competitively inhibits combination of CD36 and natural ligands of CD36, abnormal lipid excessive uptake is remarkably blocked, lipid accumulation and lipid toxicity damage in cells are effectively relieved, and the effect of inhibiting EECs lipid transport and uptake is achieved. And finally, the endometrial receptivity defect related to RIF is reversed, and the embryo adhesion and implantation capability is remarkably improved. Therefore, rutin hydrate provides a brand new strategy for developing targeted therapy drugs for RIF, especially for lipid metabolism disorder type endometrial receptivity badness, and has remarkable clinical application and transformation prospects.

The invention belongs to the technical field of pharmacotherapeutics, and particularly relates to application of cryptochlorogenic acid in preparation of a medicine for preventing and treating alcoholic liver injury. The cryptochlorogenic acid has a structural formula as shown in a formula A: # imgabs0 # experiments show that the cryptochlorogenic acid can reduce liver tissue lipid metabolism disorder and reduce cell inflammation in a dose-dependent manner, reduce the levels of ALT, AST, TG, TG and LPS in animal serum, remarkably improve alcohol-induced deletion of intestinal tight junction protein, reduce intestinal leakage, and improve the bioavailability of the liver tissue. Therefore, the compound has a certain capability of treating or preventing the alcoholic liver injury, and has the potential of being developed into a medicine for treating or preventing the alcoholic liver injury.

The invention discloses application of auricularia auricula monomer polysaccharide ME-2 in preparation of drugs for preventing and treating fatty liver diseases related to metabolic dysfunction. The research of the invention systematically proves that ME-2 has a remarkable intervention effect on the whole course of MASLD for the first time. The invention discloses a breakthrough function of ME-2 as a liver metabolism regulator for the first time: by directly correcting liver lipid metabolism disorder (such as regulating core genes such as Srebp-1c, ACC1, FASN and the like), liver fatty degeneration can be relieved in a dose-dependent manner in the whole course of MASLD, and the serum transaminase level and dyslipidemia can be reduced. Importantly, the curative effect of the traditional Chinese medicine is derived from intervention on a metabolic root source, and is totally different from a known anti-inflammatory application mechanism. Meanwhile, ME-2 has the remarkable advantages of being clear in structure, taking metabolic regulation as a core, and being safe and non-toxic, and a brand new drug candidate is provided for prevention and treatment of MASLD.

The present invention discloses a long-acting GGG triple-target agonist. The compound of the present invention simultaneously achieves excellent agonist ability at the nM level for the three targets of GLP-1 / GIP / GCGR, and can fully excite the corresponding target organ tissue cells. The compound of the present invention can promote insulin secretion and lower blood sugar; it can also inhibit food intake, delay gastric emptying, increase energy consumption, and ultimately observe a weight loss effect. The compound of the present invention can reduce pancreatic β-cell apoptosis, increase the number of pancreatic β-cells, and improve pancreatic cell function. The compound of the present invention can also improve blood lipids, reduce liver fat accumulation, and inhibit the development of liver inflammation. The compound or composition of the present invention can be used to prevent and / or treat metabolic disorders and related complications. The compound or composition of the present invention can be used to treat bone diseases related to endocrine diseases, metabolic disorders, kidney disease, etc., such as osteoporosis and osteoarthritis.

An siRNA inhibiting xanthine oxidase (XO) gene expression, a pharmaceutical composition containing the siRNA, a siRNA conjugate, and an application of the siRNA in the preparation of drugs for treating and / or preventing uric acid metabolism disorder or diseases or physical conditions caused by uric acid metabolism disorder. Each nucleotide in the siRNA is an independent modified or unmodified nucleotide, and the siRNA contains a sense strand and an antisense strand.

The invention belongs to the technical field of functional foods and health-care foods, and particularly relates to a composition with an effect of preventing and / or improving non-alcoholic fatty liver and a preparation method of the composition. The composition comprises an eggshell membrane extract, lemon concentrated powder, ganoderma sinensis powder and beet root powder. The composition prepared by the invention can be used for effectively relieving liver injury, liver lipid metabolism disorder and liver oxidative stress by reducing the liver index and weight change rate of a mouse, reducing the contents of AST and ALT in serum of the mouse and the contents of TC, TG and MDA in the liver and improving the content of SOD in the liver, so that the effect of improving the non-alcoholic fatty liver is achieved.

The invention discloses application of icariin in preparation of drugs for preventing and treating chronic kidney disease mineral substances and bone metabolism disorders. Relates to the technical field of medicine. The invention provides an application of icariin as an active pharmaceutical ingredient in preparation of a CKD-MBD treatment drug. Pharmacological experiments show that icariin can improve renal fibrosis, inhibit hyperparathyroidism, correct calcium and phosphorus metabolism, regulate and control bone metabolism related molecular expression, inhibit transdifferentiation of vascular smooth muscle cells to bone cells, inhibit vascular calcification and correct bone metabolism disorder, so that CKD-MBD is effectively prevented and treated. When icariin is used for preventing or treating CKD-MBD, the icariin is clear in component, exact in curative effect and low in side effect, and has a wide medical application prospect.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

The invention discloses the application of L. pleurotus polysaccharide in the preparation of a drug for improving alcoholic liver damage, and relates to the field of biomedicine technology. The invention finds that L. pleurotus polysaccharide can effectively protect the liver cell structure, inhibit liver swelling caused by alcohol, and reduce the liver index; downregulate the activity of liver cell damage-related biological enzymes aspartate aminotransferase and alanine aminotransferase in serum; improve the activity of liver antioxidant enzymes, inhibit the generation of hepatocyte oxidation product malondialdehyde, and reduce the oxidative stress damage of the liver of alcoholic liver mice; at the same time, L. pleurotus polysaccharide can also reduce the levels of triglycerides and fatty acids in the liver and serum, effectively improve lipid metabolism disorders, and reduce lipid accumulation; in addition, L. pleurotus polysaccharide can reduce the release of inflammatory factors such as interleukin 6, interleukin 1β and tumor necrosis factor α, promote the body's inflammation level to restore the balance state, reduce liver inflammation, and thus improve the damage of alcohol to liver tissue.

The invention relates to the technical field of pharmaceutical preparations, and particularly provides a cardiac peptide red yeast rice tablet as well as a preparation method and application thereof. The cardiac peptide red yeast rice tablet comprises the following components: cardiac peptide powder, soybean peptide powder, functional red yeast rice, D-mannitol, bovine heart peptide powder, microcrystalline cellulose, a compound nutrition enhancer and magnesium stearate. According to the cardiac peptide red yeast rice tablet disclosed by the invention, the components are used according to a specific ratio, so that the cardiac peptide red yeast rice tablet has the functions of preventing myocardial dysfunction caused by lipid metabolism disorder, improving myocardial contractility and increasing the survival rate of myocardial cells, and a product suitable for improving cardiac functions can be provided.

Provided are an NPQ-IgG2 / Fc fusion protein and the use thereof. The fusion protein comprises an NPQ polypeptide and a human IgG2 / Fc region, and can be used for treating glucose metabolism or lipid metabolism disorder-related metabolic diseases, such as liver diseases including fatty liver, and diabetes.

The invention discloses application of anagloside C in preparation of a medicine for treating diabetes, and relates to the technical field of biological medicines. The research finds that after ANC administration treatment is carried out on a T2DM animal model db / db mouse, the blood glucose level is reduced in a dose-dependent manner, the insulin sensitivity is obviously increased, the lipid metabolism disorder is improved, and the ballooning and fatty degeneration accumulation conditions in the liver tissue are relieved; a Western blot detection result shows that the ANC has the effects of activating a db / db mouse liver tissue AMPK signal, inhibiting a TXNIP / NLRP3 inflammasome signal and protecting an insulin signal. The results show that ANC has a therapeutic effect on T2DM. On the basis, the ANC can inhibit TXNIP / NLRP3 inflammasome signals through AMPK dependence to improve liver insulin resistance, and therefore the effect of treating diabetes mellitus is achieved.

A composition comprising a Christensenella sp., a culture thereof or a metabolite thereof, for use in the method of treating, preventing, or alleviating metabolic disease or the disease caused by a metabolic disorder in the subject. The metabolic disease or the disease caused by a metabolic disorder includes obesity, obesity-induced metabolic disorders, diabetes, inflammation, liver and kidney diseases, liver diseases, cardiovascular and cerebrovascular diseases and the like.